PILA PHARMA AB

Norra Vallgatan 72
211 22 Malmö
Sweden

pilapharma.com

Malmö, 05 March 2026

PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE – CEO & FOUNDER'S PARTICIPATION DISCLOSED

PILA PHARMA AB (publ) (FN STO: PILA) ("PILA" or "the Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, informs of the conversion of TO2 warrants to shares, and the disclosure of participation from management members.

- The subscription period for exercise of the warrants of series TO2 took place during the period from and including 5 February 2026, up to and including 15 February 2026.
- The subscription price per share for exercising the warrants of series TO2 was determined to SEK 1.50
- In total, 1,798,853 warrants of series TO2 were exercised for subscription of 3,597,706 shares, meaning that approximately 12.03 percent of all outstanding warrants of series TO2 were exercised for subscription of shares.
- For existing shareholders who did not exercise any warrants of series TO2, the dilution amounts to approximately 7.88 percent.
- In total, the Company received approximately SEK 5.396.559 before issue costs.
- The new total of outstanding shares is 45,682,121.
- CEO Gustav H. Gram personally exercised a total of 33,817 warrants for a total of 67,634 new shares at a price of SEK 101,451. Following the transactions, Mr. Gram directly and indirectly holds 276,213 shares in the Company.
- CSO and Founder Dr. Dorte X. Gram, through jointly owned investment company, Gram Equity Invest AB, exercised a total of 167,102 warrants for a total of 334,204 new shares at a price of SEK 501,306. Following the transactions, Dr. Gram directly and indirectly holds 6,303,507 shares in the Company.

The transactions have been reported to the **Swedish Financial Supervisory Authority (Finansinspektionen)** in accordance with applicable regulations.

With the conclusion, the rights issue announced on 19 June 2025, has been fully concluded. In total, PILA PHARMA has been received approximately SEK 35.3 million before costs.

The proceeds will finance progression of the company's lead candidate, an oral, small molecule TRPV1-inhibitor, into a clinical trial in obesity and the rare disease erythromelalgia.

For more information:
CEO, Gustav H. Gram
Email: ghg@pilapharma.com

Pila Pharma's share ticker PILA is subject to trade on Nasdaq First North Growth Market, Sweden with **Aqurat Fondkommission AB** as Certified Adviser. Contact: M: ca@aqurat.se - T: +46 (0)8 684 05 800

About PILA PHARMA AB (Publ)

PILA PHARMA is a Swedish biotech company based in Malmö, Sweden. The aim of the company is to develop TRPV1 inhibitors as a novel treatment of obesity, type 2 diabetes and potentially of other diseases with an inflammatory background. The Company owns a TRPV1 asset with data and chemical entities including the development candidate XEN-D0501. Further, the Company owns use-patents covering the use of TRPV1-antagonists for treatment of obesity and diabetes and intends to submit further patents regarding the synthesis, formulation, or use of XEN-D0501 or back-up compounds. In July 2022, the Company was awarded orphan drug designation ("ODD") for XEN-D0501 as a treatment for a painful rare disease erythromelalgia. PILA PHARMA currently focuses on obesity and type-2 diabetes whilst also retaining a focus on licensing opportunities for development of the candidate for erythromelalgia and abdominal aorta aneurysm.

About XEN-D0501 and TRPV1 antagonists

XEN-D0501 is a selective, synthetic potent small molecule TRPV1 inhibitor that was in-licensed in 2016. The drug candidate is a small molecule currently formulated in a simple and stable tablet formulation.
TRPV1 inhibitors that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. PILA PHARMA's founder and current CSO Dorte X. Gram, is the inventor of the principle of treating diabetes and obesity with TRPV1 inhibitors – a discovery-by-surprise during her PhD studies at Novo Nordisk, Denmark. Here she discovered that TRPV1 inhibitors would prevent glucose intolerance and body weight gain in spontaneously obese pre-diabetic rats. These results pointed to a new and previously undiscovered role of TRPV1 in regulating both blood glucose and body weight. Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.
PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by in people living with obesity and type 2 diabetes. Further, in PP-CT02, it was demonstrated that XEN-D0501 (administered as 4 mg bi-daily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. ANP, a cardiovascular biomarker for heart failure, was also highly statistically significantly reduced.
During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. The next step is now to submit a clinical trial application for a dose-finding study in people living with obesity. The clinical trial application should be submitted around the end of Q1 2026. The ambition is to create a comprehensive and meaningful data package that supports XEN-D0501 as an oral, potential first-in-class drug candidate.

About obesity and diabetes

Obesity (BMI >30) is pandemic in its essence with estimates of more than 1 billion people living with it in 2025. Overweight (BMI >27) is also at staggeringly high levels with estimates of 4 billion people globally.
It is most often preceding the development of type 2 diabetes and is a serious risk-factor for not only developing type 2 diabetes but also co-morbidities resulting in "*whole body dysfunction*" and subsequent development of several diseases. The accumulated effect is a year-long reduction in quality of life for obese people with or without diabetes. Obesity leads to an increased risk of developing cardiovascular disease that eventually results in premature death and shortening of life duration. Recent advances and the development of effective anti-obesity drugs has proven that pharmacological weight management is possible and leads to obvious quality-of-life and longevity benefits for people living with obesity. Even long-term, public health costs are expected to be reduced if the clinically negative effects of the obesity pandemic are limited. This has sparked a general interest in future potential oral treatments that can meet the accessibility criteria needed to stimulate enormous and growing demand.
Diabetes is a similar spanning pandemic with strong ties to obesity, and with a staggering estimated prevalence of more than 828 million people living with diabetes corresponding to approximately 8-10% of the global adult population. Among these, its estimated that more than approximately 90 % of all diabetics suffer from type-2 diabetes, whilst approximately less than 10% suffers from type-1 diabetes. Despite recent therapeutic advances, large and growing unmet needs exist both from efficacy, safety, and accessibility standpoints.

Having previously completed two clinical trials in people living with overweight and diabetes, the Company is now, together with its clinical partner, preparing a clinical trial application with estimated submission around end of Q1 2026.

About erythromelalgia

Erythromelalgia is a rare disease where neurogenic inflammation plays a role in the development of symptoms. The disease can cause near-constant or episodic pain (ranging from mild tingling to severe burning sensations), and redness to extremities. It most commonly affects the feet but may also occur in the hands, face, or other parts of the body with both nerves and blood vessels involved. Symptoms are frequently managed through avoidance of pain triggers. The disorder can be extremely debilitating, with a significant negative impact on quality of life and with potential to impact mortality rates among young people and the suicide rates among adults. There are no current treatments available to patients, but it is widely believed by doctors that an oral solution with systemic effects would be highly preferable.
PILA PHARMA has made a draft clinical development plan for this project and the project is available for out-licensing. The Company is currently preparing to submit a clinical trial application with estimated submission around end of Q1 2026.